RH 1

Drug Profile

RH 1

Alternative Names: RH-1

Latest Information Update: 10 Sep 2012

Price : $50

At a glance

  • Originator Cancer Research Technology; University of Colorado at Denver; University of Salford
  • Developer Allos Therapeutics
  • Class Antineoplastics; Aziridines; Benzoquinones; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 06 Sep 2012 Allos Therapeutics has been acquired by Spectrum Pharmaceuticals
  • 09 Mar 2009 Rh 1 is available for licensing outside the US (http://www.allos.com)
  • 14 Nov 2007 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top